Public Profile

CYTOMX THERAPEUTICS INC

CytomX Therapeutics Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 2011, the company has made significant strides in the field of protein engineering, focusing on its proprietary Probody™ platform, which enables the creation of targeted therapies that minimise off-target effects. CytomX operates primarily in the oncology sector, with a commitment to advancing treatments that enhance patient outcomes. The company has achieved notable milestones, including strategic partnerships with major pharmaceutical firms, which bolster its position in the competitive biopharmaceutical landscape. With a robust pipeline of unique therapeutics, CytomX Therapeutics continues to redefine cancer treatment paradigms, making it a key player in the industry.

DitchCarbon Score

How does CYTOMX THERAPEUTICS INC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

CYTOMX THERAPEUTICS INC's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

CYTOMX THERAPEUTICS INC's reported carbon emissions

CytomX Therapeutics Inc, headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that CytomX may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the biopharmaceutical industry increasingly prioritises sustainability, it will be essential for CytomX to establish clear climate commitments and emissions reduction initiatives to align with industry standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. CYTOMX THERAPEUTICS INC's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. CYTOMX THERAPEUTICS INC is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

CYTOMX THERAPEUTICS INC is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers